These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16319514)

  • 1. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
    Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
    Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
    Nakamura K; Yamaguchi T; Ishihara T; Kobayashi A; Tadenuma H; Sudo K; Kato H; Saisho H
    Br J Cancer; 2005 Jun; 92(12):2134-9. PubMed ID: 15942632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
    World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
    Sai S; Toyoda M; Tobimatsu K; Satake H; Yasui H; Kimbara S; Koyama T; Fujishima Y; Imamura Y; Funakoshi Y; Kiyota N; Toyama H; Kodama Y; Minami H
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):65-71. PubMed ID: 33098471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
    Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T
    Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
    Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
    Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
    Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure.
    Okuno M; Mukai T; Iwata K; Takagi A; Ito Y; Ohashi Y; Tezuka R; Iwasa Y; Iwata S; Tomita E
    Med Oncol; 2024 Jul; 41(8):195. PubMed ID: 38967720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
    Saito K; Isayama H; Nakai Y; Takahara N; Ishigaki K; Takeda T; Hakuta R; Saito T; Uchino R; Kishikawa T; Hamada T; Mizuno S; Sasaki T; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
    Invest New Drugs; 2019 Apr; 37(2):338-344. PubMed ID: 30411217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
    Nakai Y; Isayama H; Sasaki T; Sasahira N; Ito Y; Kogure H; Togawa O; Matsubara S; Arizumi T; Yagioka H; Yashima Y; Kawakubo K; Mizuno S; Yamamoto K; Hirano K; Tsujino T; Ijichi H; Toda N; Tada M; Kawabe T; Omata M
    Oncology; 2009; 77(5):300-3. PubMed ID: 19923869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Sakai D; Kodama Y; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2012 May; 69(5):1181-8. PubMed ID: 22237958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
    Kasuga A; Okano N; Naruge D; Kitamura H; Takasu A; Nagashima F; Furuse J
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):457-64. PubMed ID: 25547407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
    Song H; Han B; Park CK; Kim JH; Jeon JY; Kim IG; Kim HJ; Jung JY; Kim JH; Kwon JH; Jang G; Kim HY; Kim HS; Choi DR; Zang DY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):845-52. PubMed ID: 23978987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
    Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
    Nakai Y; Isayama H; Saito K; Sasaki T; Takahara N; Hamada T; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):911-5. PubMed ID: 25143299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
    Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
    Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.